Al's Comment:

 We received generous donations and are able to reopen the program!  Do not feel bad about asking for help. That is what we are here for. We understand what you are going through and want to help. If you could use the help - apply!

 


Posted on: 01/04/2022

Musella Foundation Copay Assistance Program is now open and another drug added to coverage list!

Our copay assistance program is now open.  We have received some very generous donations to the program - thank you to the donors!

We have added the drug Lomustine (also known as Gleostine or CCNU) to our coverage list!

The program is open to patients with a high grade primary malignant brain tumor, and who have insurance, but who could use help with copayments for Temodar, Avastin, Lomustine or Optune (and their generics). There is an income limit - but it is very generous.  We award grants of up to $5,000 per year to help with these copays,  See braintumorcopays.org for details and to apply!

The program opens and closes to new and renewal applications as we have funding. When the program closes - we still pay the claims from patients who were already approved - we set aside their $5,000 when it is approved.  If they do not use the entire $5,000 at the end of the 1 year grant, it goes back into the pot for us to use on other patients!

If you think you may need help, apply. Never be shy or embarrassed to ask for help.  We went through this and understand the financial pressures that a malignant brain tumor can cause, even if you were OK financially before. We are here to take some of the stress off of you and try to make the process easy. 

We never know how long the program will remain open - it depends on how many applications we receive. We think it will stay open for 2 months or so this time.

If you have questions or any trouble with the application, contact us by using the 'Contact Us' link on the website or call us at 888-295-4740.

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!